Good morning, and welcome to the First Quarter 2012 Earnings Release Conference Call for FMC Corporation. [Operator Instructions] As a reminder, this conference is being recorded. Thank you. I will now turn the conference over to Mr. Brennen Arndt. Mr. Arndt, sir, you may begin.

Thank you, and welcome, everyone, to FMC's First Quarter 2012 Conference Call and Webcast. Joining me today are Pierre Brondeau, President, Chief Executive Officer and Chairman; and Kim Foster, Executive Vice President and Chief Financial Officer. Pierre will begin the call with a review of our first quarter performance, Kim will then report on our financial position, and Pierre will complete the call by providing our outlook for 2012 and by taking your questions. Joining Pierre and Kim for the Q&A session will be Milton Steele, President, Agricultural Products; Michael Wilson, President, Specialty Chemicals; and Mark Douglas, President, Industrial Chemicals. A reminder that our discussion today will focus on adjusted earnings for all income statement and EPS references under the heading entitled Glossary of Financial Terms on our website available at fmc.com, you will find the definition of adjusted earnings and certain other non-GAAP financial terms that we may refer to during today's conference call. Also, on our website, we posted our current 2012 outlook statement, which provides our guidance for the full year and second quarter 2012, as well as a reconciliation to GAAP of the non-GAAP figures we will use today. And finally, share and per share financial data discussed today do not reflect the 2-for-1 stock split of FMC's common stock that is payable on May 24, 2012, to stockholders of record of its common stock as of the close of business on May 11, 2012. It's now my pleasure to turn the call over to Pierre Brondeau. Pierre?

Thank you, Brennen, and good morning, everyone. As you saw in our earnings release, our first quarter results provided a very strong start to what we expect will be another record year for FMC. Summarizing our first quarter 2012 performance. Sales of $951 million increased 18% above last year's first quarter, and adjusted earnings of $1.94 per diluted share grew 30% versus a year-ago quarter. Agricultural Products delivered a robust performance in the quarter. Sales of $454 million increased 32%, driven by broad-based growth across Latin America, North America and Asia. Segment earnings of $130 million increased 29% versus the year-ago quarter, driven by the sales gain, partially offset by higher spending on several growth initiatives. In Specialty Chemicals, the performance met our expectations. Sales of $216 million were up 3% as higher selling prices were achieved in all businesses, particularly in food, pharmaceuticals and lithium primary markets. Partially offsetting these pricing gains were lower volumes related to downtimes associated with capacity expansions and plant tie-ins at our Argentina lithium facility, and to a lesser degree, at BioPolymer's alginates facility in Norway. Segment earnings of $44 million were down 1% as the sales gain were more than offset by higher weather-related operating costs in lithium, plant downtime effects, higher raw material costs and increased spending on targeted growth initiatives in BioPolymer. In Industrial Chemicals, sales of $273 million increased 12%, driven by higher selling prices, especially in soda ash, and volume growth in soda ash and specialty peroxygens. Segment earnings of $48.1 million increased 19% as the result of the sales gains, favorable export mix in soda ash and the continued mix shift in peroxygens towards specialties markets. Taking a look at total company sales on a regional basis in the first quarter. Sales in Latin America demonstrated the highest…

Thanks, Pierre, and good morning, everyone. First, share repurchases. Recall that in November of last year, we committed to repurchase $200 million of shares by the end of the first quarter of 2012. Following that commitment, we repurchased $55 million of shares in the fourth quarter of last year. And I'm pleased to report that in the first quarter, we completed the $200 million program with the repurchase of approximately $145 million of shares. At the start of the second quarter, we have $245 million of repurchased capacity remaining under an existing board authorization. Going forward, we will continue to govern and balance the pace of execution of our share repurchases with our capital needs to drive organic growth in the investment and targeted external opportunities. Moving to our recent announcement of a 2-for-1 stock split. Following our shareholders' approval of an amendment to increase the number of authorized shares, last week, our Board of Directors declared a 2-for-1 stock split of our common stock. The split will be affected in the form of a distribution payable on May 24, 2012, to shareholders of record as of the close of business on May 11, 2012. Trading in the common stock will begin on a post-split adjusted basis on May 25, 2012. I'll close by reaffirming guidance for certain financial items, which we gave you during last quarter's conference call. Free cash flow for 2012 is reconfirmed at $200 million to $225 million for the year. Our capital expenditure forecast is reaffirmed at $250 million, and our tax rate for the year is reaffirmed at 27%. With that, I'll turn the call back to you, Pierre.

Thank you, Kim. Regarding the outlook for the full year of 2012, we have raised the midpoint of our previous outlook and now expect adjusted earnings of $6.80 to $7.05 per diluted share, a 16% increase above last year at the midpoint of this range. Our Agricultural Products segment expect to achieve its ninth straight year of record earnings, up 10% to 15% over last year. Sales gain is the result of volume growth in all regions, particularly in Latin America, North America and Asia, due to strong market condition and growth from new and acquired products, partially offset by higher spending on targeted growth initiatives. And our Specialty Chemicals segment expect to achieve its seventh straight year of record earnings, led by the eighth straight year of record earnings in BioPolymer. Segment earnings are expected to be up approximately 5%, reflecting higher selling prices across the segment and volume growth in BioPolymer and lithium specialties. Partially offsetting this growth are higher lithium operating costs in the first half of the year, higher raw material costs and increased spending on several growth initiatives in BioPolymer. As I mentioned earlier, in our Lithium business, we expect a significant sequential pickup in sales and earnings in the second half of the year compared to the first half. In our Industrial Chemicals segment, we expect earnings to be up 20%, driven by higher volumes and selling price in soda ash and specialty peroxygen, augmented by the continued mix shift towards specialty peroxygens. Moving to our outlook for the second quarter of 2012. We expect adjusted earnings of $1.65 to $1.85 per diluted share, a 14% increase in the midpoint of this range. In Agricultural Products, we expect earnings to be up about 5%, reflecting growth in all regions, partially offset by the shift…

[Operator Instructions] And our first question will come from the line of Frank Mitsch with Wells Fargo Securities.

Thank you for providing that pull forward on the Ag side. I was wondering if you could do something similar in terms of the lithium weather impacting Q1. Obviously, specialties came in a little bit lighter than expected. What -- how -- could you give us the order of magnitude of that -- of the negative impact due to weather for lithium in Q1?

Yes, Frank, this is Michael Wilson. In terms of the weather impacting Q1, I would say it was probably $1 million to $2 million of EBIT.

All right, so not too significant. And sticking with that, you saw the headlines that the Argentine government is looking to take over YPF. What concerns, if any, do you have with respect to your position in that market?

Well, right now, as you know, we do have agreement with the government in terms of how we operate and tax and cash repatriation. But clearly, we are taking a pause in looking at where we are going with our expansion. I think the way the business is operating today is fine, but as you know, we are going to be very quickly even with the current expansion, again, at a 100% capacity utilization. And we are studying the situation in Argentina to make a final decision in the next few months about our future expansion. I think there's a lot of moving parts today in Argentina, and it is very hard for me to make a full commitment to the next step of expansion until we have a better picture of what is going on. And we are talking with authorities over there in Argentina.

All right, great. So it's something that sometime in this late summer and so forth, we'll have a better idea what FMC's plans are there?

Absolutely, Frank.

All right. And then lastly, you mentioned that you're expecting a very positive growth on the soda ash business and pricing up year-over-year in that business, although you did mention a competitive threat to the export market. Can you talk a little bit more about that?

Yes, what -- I mean, if you look year-on-year, we're going to have very solid -- and it's part of our guidance and what we've said, very solid year-on-year pricing. Today, we have started looking forward to be prudent, and that's why despite the very strong first quarter, you see that we are keeping above the year number for Industrial Chemical in term of earnings growth at the same level. And we are looking at a 20% despite a stronger first quarter than we're expecting. We mentioned the fact that we had a very favorable export mix, which should re-establish and be a little bit less favorable in the second quarter. And we have seen some sign of price decrease in Asia around soda ash because of the reduction in demand versus what we're expecting. It's not big, but it's there, and we just took the prudent approach to have a more conservative pricing from ANSAC in Asia and only in Asia. The rest of the world stays about what we're expecting.

All right, great. Well, you certainly -- your results here in the first quarter certainly made your guidance for Q1 very prudent and conservative, so -- well, I guess we'll expect the same for the balance of the year.

And the next question comes from the line of Mike Harrison with First Analysis.

I was just hoping to talk about the soda ash business a little bit. You had talked about seeing some increased royalty payments during 2012, and I was wondering if that had an impact in Q1 or maybe kind of what the timing is. And can you remind us what the magnitude of that higher royalty impact will be?

Yes, Mike, it's Mark Douglas here. We'd never actually gave an order of magnitude when we talked on the fourth quarter call in terms of what the royalties was. The rate has moved from 2% to 6% on any federal land that we mine. We don't actually break that out, but yes, it did have an impact in Q1, and it will have an impact in the rest of the year on a quarterly basis as we go forward. But we did not break that out.

And the impact, compared to Q1, should be about the same as the year progresses?

It's not easy to say. It's not actually as simple as that because as we mine, we go through different leases, so it varies quarter-to-quarter, but we don't actually break that out in terms of quarterly analysis.

And we started to move into the new royalty partially during part of last year, so it's not -- I mean, the impact was high in the first quarter, but it varies from quarter to quarter.

All right. And then in the BioPolymer business, you referred to improved mix in the food business and specifically noted dairy beverages in Asia. Are we going to continue to see within that business that your higher-value products are growing faster than other areas? And can you maybe just give us a little bit more color on how much higher the margins are in something like dairy beverages versus the average for the food business?

I think the -- more than talking about dairy or other application, I would say that we have 3 product lines in our BioPolymer business: carrageenan, alginate and MCC. And by far, the highest profit, faster growth is our MCC product line, and that if you look, that's where all of our investment are going. So I think this business will grow faster and faster when the MCC part of that business will get bigger because that's the place which is commanding potentially high single-digit or double-digit growth rates, while the other businesses are just low single-digit growth. So MCC is really -- and you're right, MCC has application in the dairy market in Asia; very fast growth in Asia; double-digit growth in Asia. It has application also in pharmaceutical, protein beverage, so it's a broad range of application but more specialty and more differentiated.

All right. And then the last question I had is just maybe to elaborate a little further on lithium and the downtime. It sounds to me like your downtime, because of the adverse weather you saw, the downtime and the startup of the capacity expansion is maybe taking a little bit longer than you had initially anticipated. You talked at first about 6 weeks of downtime during the first quarter. Is that more or less where you are, or maybe a little more color there?

Yes, the downtime itself in term of time was about the same. It was more difficult. We had issues in bringing some of the equipment we need because of the weather on the road. But the length of the downtime was about the same. The problem is the downtime, combined with the weather, created some issues to operate the plant. Even the pod was working the way it was working at full capacity. We also had dilutions, very significant dilutions of the ponds, which is forcing us to work with brine which is more diluted. So we had -- it's much more a combination of 2 negative effects together, which have created a situation where in the first quarter, the performance was low compared to -- significantly below what we had a year ago. We will still see that effect in the second quarter because even if the tie-ins of the plants are done, we're going to be having diluted ponds, and we're going to be operating with the brine which is less concentrated, which will create less product from the plant in a high operating cost. Things are starting to get better in the third quarter. So third quarter, you will see sequential and year-on-year improvement in the EBIT, not yet at full capacity. I think we will have fully recovered from all of that, and the lithium business will be at full performance in the fourth quarter. So you will see sequential improvement from first quarter to the fourth quarter with the start of the ramp-up, the most visible start of the ramp-up being in the third quarter.

Our next question comes from the line of Kevin McCarthy with Bank of America Merrill Lynch.

Pierre, if you ultimately elect not to proceed with a follow-on expansion of lithium capacity in Argentina, can you give us a sense of the other potential options available to you? For example, does FMC today have access to any reserves outside of Argentina and elsewhere in Latin America or North America, for example?

Well, today, the places where we would be -- first of all, let me say that we are pausing and observing and negotiating, but we still believe Argentina is our #1 option for expansion. So we cannot make a decision today because of the political situation. But it still remains our #1 opportunity. If it is not a place where we would increase, the options we have are, clearly, you know that Chile is a place today which is opening up to companies. Now we would have to start a grassroot plan. So we would not any longer be talking about major expansion in 2014. I would most likely push that to 2016-plus. We also have possibilities in Australia and possibilities in China. So we are right now looking at all of our options we might be able to use, but Argentina remains our priority. Argentina, by far, is the cheapest and the fastest way to bring additional capacity.

Okay. And then if I may switch gears to soda ash, can you give us an update on how you would assess prospects for a restart of the remaining idle capacity that you have at Granger? And then a second question on mix, I think you alluded to favorable mix. Is that essentially more tons flowing into Latin America versus Asia? And would you expect the geographic mix to be different this year relative to last year in that regard?

First, let me talk about the expansion. I would say that the probability that we'll expand Granger is very high. The question is only the timing. As you know, we do have 3 major projects to be undertaken. We are -- we will be building a large MCC plant in Asia. We do have the doubling of the capacity in Argentina potentially for lithium, and we do have the Granger 2 expansion. So we have to prioritize and decide what is the best timing for all of this. I would say that we will be, as Frank said before, maybe by end of the summer, fall, we'll have a better idea of where we're going with the lithium timing. And I would say that by the end of the year, we'll have a better idea of where we are going with the Granger timing. So all of those are most likely to happen. It is just a timing of one versus the other. I would say the one which is the most likely to take off first and be quickly undertaken is the MCC plant in Asia. Regarding the mix, we believe the mix is going to be -- the export mix is going to be the same year-on-year. The only difference is more of a quarter. We had left shipment towards Russia or Eastern Europe or some other countries which are more difficult and less favorable from a mix standpoint, but we're going to ship more toward those in the second quarter. So it's more of a quarter balance than it is of a year balance.

The next question comes from the line of John McNulty of Crédit Suisse. John P. McNulty - Crédit Suisse AG, Research Division: Just a couple of quick questions. On the -- in Ag, in the North American pull-forward that you saw or you took from a little bit maybe of the second quarter earnings and pulled it into the first, can you please discuss how we should think about the margin on that business compared to the rest of your core business in Ag?

Margins are about the same. What we believe is we believe that we pulled forward about $5 million to $8 million of EBIT into the first quarter. That's about the number we are estimating. Those are speculations. I mean, it's sometimes very hard to know if we could stay strong on EBIT more, but we're expecting that -- North America tends to have higher margins than places like Brazil, but there is not a very large difference. And assuming about the same level of margin, we pulled forward $5 million to $8 million of EBIT. John P. McNulty - Crédit Suisse AG, Research Division: Okay, great. And then for the Environmental Solutions opportunity, and I guess, the segment that you're going to be carving out going forward, is this more of a management direction kind of change in terms how you resource it with management, or should we be thinking about M&A and capital projects that are incremental to what we've been looking for in some of these businesses in the past?

That's a good question. A couple of things. First of all, there is a management change, which means we wanted to create an organization where people would wake up in the morning thinking solely about that business and would be capable of leveraging the resources we have a bit spread around that business around the company. So we wanted a much more focused accountable management for that space and bringing together the technologies, allowing better innovation. I do not foresee beyond what we have announced any significant capital spending, but I do foresee potential M&A activities. John P. McNulty - Crédit Suisse AG, Research Division: Okay. And then just the last question with -- somewhat tied to that, with the venture that you have on some of the trona opportunities, can you discuss what you've been seeing so far since you've started that venture and when we might be seeing some sort of a growth pick-up there?

Yes, John, this is Mark. I assume you're referring to Natronx, our DSI joint venture. John P. McNulty - Crédit Suisse AG, Research Division: That's right.

With the Cross-State Air Pollution Rules being stayed from April of this year until early next year, obviously, we've seen customers being very cautious in terms of what they are looking at for trials, et cetera. But for us, it's very much a case of not if the rules are in place, but when. And we fully expect that to occur early next year. So our plant expansion that we have underway in Wyoming is scheduled to be on stream at the end of this year, and that is on track. So we're very bullish on this market. We recognize there's been a delay from the April of this year to early next year, but it's very much a market that we expect to grow. So you should be looking for some impacts as we go through next year.

The next question comes from the line of Rosemarie Morbelli from Gabelli & Company. Rosemarie J. Morbelli - Gabelli & Company, Inc.: Going back to the soda ash for a second, is your -- the delay of your decision, Pierre, on adding additional capacity at Granger linked to the higher competitive environment in Asia and lower prices? Do you feel that you have more time in front of you before you decide what to do depending on what happens there?

Not at all. We have a very positive outlook. If you look at -- an expansion in Granger would bring about 700,000 tons of products in the market, which is 45 million, 50 million tons a year, where you have growth, which is in the mid-single digits. So -- and if you add to that the low manufacturing costs we had, it would not be an issue at all to push this product into the market without even creating more price pressure on the world. So the vision is not due to market constraints. We feel very strong about the market today and where we're going for this year and next year. It is more a prioritization within the company in term of resources. Those 3 projects represent significant capital investment, which could dimension in the order of $0.5 billion, and they all require -- if not more actually, and they all require significant engineering resources. And I just want to make sure that we are resourcing all of those projects in an appropriate way to successfully deliver on each of them. That's why we have to maybe stagger the start of each of those projects and not undertake everything at the same time. Rosemarie J. Morbelli - Gabelli & Company, Inc.: Okay, that is helpful. And at the end of the fourth quarter, you mentioned, if my -- if I am remembering correctly, that the 8 transactions that you did in 2011 were going to -- would add about $90 million to 2012 revenues and $15 million, 1, 5, of EBIT or $0.07 per share. Are you on track to get those particular increments, or are you ahead there or behind? Could you give us a better feel for what -- bring us up-to-date as to how they are performing?

Absolutely on track. Some, maybe positive news, if I look beyond 2012 on some of the product line we have acquired, which are showing greater opportunity I'm thinking for -- about Ag, for example. But yes, for 2012, completely on track. And we will be -- as you know, we give every other quarter, we will give an update on 2015, and that will be part of monitoring. So we'll talk more about that when we do that, but we're on track. Rosemarie J. Morbelli - Gabelli & Company, Inc.: Okay. And if I may ask one last question on lithium. The stated goal is that there will be 1 million EV vehicles on the road by 2015. But we are beginning to read that actually, if we have 200,000, that will be good. Is that -- if this is the case, would that change the growth rate you're anticipating, and therefore, there is not as much of a rush or pressure to add additional lithium in order to supply a market that may grow slower than previously anticipated?

No. If you look at the way we are building the capacity, as well as what has been announced by some of our peer companies in this market, the kind of capacity increase we are planning to add in the 2014, 2015 time frame will be absorbed by the market outside of the EV market. So it is not a big decision. We will be building the capacities to double the full capacity in 2 different tranches. Now if EV is slower than what we are seeing, that could impact the timing at which we have tranche 2 of the capacity expansion. But right now, where most of the industry is in capacity and the growth of the market outside of EV or, let's say, of the car industry, outside of the car transportation industry, we have no issue in the first step of the expansion. Same ways is being -- it's the same for our competitors. I think the question will come for the next step in the '16, '17.

And our next question will come from the line of Mike Sison of KeyBanc.

In terms of your outlook for Industrial Chemicals, I thought you had noted initially that Granger will be running full out. Will it still be pretty much running full out for this year?

Correct. It's running full out.

Okay. And then just when you talked about some of the pricing in soda ash slipping a little bit, is that -- just to clarify, is that more supply-driven or was it really more demand-driven?

I think we believe, what we understand and also, again, it's not like we have 6 months of price decrease behind us, but the signs we are reading is that there has been capacity buildup in the end of last year in China and a market growing a little bit slower than we're expecting, which has been pushing some of the Chinese competitors to push product outside of China into their export market, and those product came head-to-head against ours, and that has created a little slowdown in the price increase. Now pricing are still robustly above where they were last year. Don't get me wrong. It's not a decrease versus last year price. The price is actually going up. The problem is what we see today is the ramp-up of the price in Asia might not be as steep as what we're expecting, and we are slowing down a bit the curve but still contemplating year-on-year price increase.

Got it. And it sounds like demand is still pretty solid over there. It's not deteriorating too quickly.

Yes, the demand is solid, and we are at full capacity in the summer 2012 expansion, and it's all soda.

Great. And last question, the Bayer acquisition, the fungicide business that you bought from Bayer, the exciting potential -- potentially, sorry. Is -- can you give us an update there or how that business did in the first quarter and what your outlook for that business could be for the next couple of years?

The business actually is doing quite well. We are still in the integration process. It's quite a complex process to bring all of the Bayer product registration and all of the supply chain issues. So we are still in the integration phase, but I have to say that we are very pleased with that acquisition. We're very pleased with our cooperation with Bayer, which is extremely positive. And we do see more and more opportunities. We just had a review, for example, in Latin America. We do see great opportunities beyond what we're expecting. So when I answered the question before, we're on track, and say maybe beyond 2012, we have some good surprise there, that's one of the one which is going to grow faster than we are expecting.

Your next question comes from the line of Laurence Alexander of Jefferies. Lucy Watson - Jefferies & Company, Inc., Research Division: This is Lucy Watson on for Laurence today. You've mentioned that BioPolymer sales were up solidly with a good contribution from price. Were you able to achieve the full targeted 15% price increase that you announced in December? And what is your current overall MCC utilization rate?

Yes, in terms of the price increases, we had very successful price increases across BioPolymer. Unlike some of the other businesses, BioPolymer increases prices more on a customer-by-customer basis as opposed to across-the-market. So it really varied across the product line. But then in terms of the volume, we did add capacity last year, we filled out a great deal of that capacity. And as Pierre mentioned, we have another expansion of MCC coming on in the fourth quarter of this year, so we think that's going to be well-timed to bring that on given the market growth that we're seeing. Lucy Watson - Jefferies & Company, Inc., Research Division: Okay. And also in your prepared remarks, on regional terms, you mentioned some timing impacts on sales in Central and Eastern Europe and in Turkey. Could you expand on that?

Yes, those are small volumes from small sales. It's part also of what I discussed around the -- it had a positive impact in term of the mix for soda ash, where we saw more sales going to non-Eastern Europe, Russia countries and more toward western, toward Latin America or Asia, which was a positive mix. But it's -- we are pretty small over there, so it's not a -- it had a positive impact on earnings, but it's not a big volume contributor. Lucy Watson - Jefferies & Company, Inc., Research Division: Okay. And just one more. Is it possible to put the Agricultural Products sales increase by product or maybe to provide what level of growth you saw in herbicide versus fungicide?

No, we don't usually break down herbicide, fungicide or our product line in term of growth.

And our next question comes from the line of Dmitry Silversteyn of Longbow Research.

A couple of questions, if I may. To follow up on the last question and not focusing specifically to the question that Mike asked and not focusing specifically on the business you bought or the product you bought from Bayer. But if you take a look over the past year, you've made several product acquisitions. If you look at them in aggregate, could you give us an idea what the contribution on an annual basis to revenues is in the Ag business from these new products?

Yes, I would say that those product will be in the range of $50 million.

$50 million, 5-0?

5-0, $50 million or slightly more.

Okay, okay. That's pretty significant. Great.

Yes, it is. Yes.

Secondly, when you are bringing on -- you talked about the lithium problems that you're continuing to have as far as weather is concerned but -- in the rains and the dilution. But as far as the cost of bringing on or starting the ramp-up of production in the third quarter, should we expect that to be dilutive to margins until you ramp up fully and then see the full benefit in the fourth quarter, is that the right way to think about it?

Lithium, yes. I mean, the way you have to look at lithium is, up to the fourth quarter, we will not be at the full sales and earnings potential of the business, so you won't see an improvement in the second quarter versus the first quarter, versus only a long way from the potential as we recover. Sales quarter, as you start to feel better, but we are still operating at higher costs, but it's improving for the third quarter, and end of the third quarter and the fourth quarter is what we know and believe we will be at the full operations of the business, which means we'd be operating at a lower cost, with margins more in line with our expectation in historical margin and higher volumes because we'll benefit fully from the expansion.

So the full impact, if you will, when we looked to, is really in 2013 when you're going to have all 4 quarters of higher volume and a better margin business?

You're absolutely correct. I think we're going to see a very different performance of the Lithium business in 2013, which will be a continuation of the performance with the same ratio in sales that we're going to have in the fourth quarter.

Got it, got it. Just staying with the specialty business, the investing that you talked about doing in the BioPolymer's area, can you talk about sort of the magnitude of the investments that you're making and where is it going? Is it personnel? Is it marketing? Is it product line expansions or capacity expansions? And then talk a little bit about the timing of all these initiatives and what's the payoff and when is the payoff.

All right. We -- the capital spending for a plant like that, we are still at the pre-engineering phase, so it's going to be plus or minus $50 million, but I would say in the range of $100 million. And we would be moving into a full-mode detailed engineering before the end of the year. We believe a startup before the end of 2014, Michael, is correct?

Yes.

Before the end of 2014. The $100 million is capital spend. We do have an organization today which is ready to bring to market. I mean, we still have to hire, I'm sure, a few salespeople. But overall, we do have an organization which is in place with the technical and sales structure to sell the product which will come out of this plant. I don't know if you've seen but we have opened up a lab in Singapore this quarter, in the first quarter, where we had about 50 customers that was there. We do have expanded our lab and offices in Istanbul. We have a new lab also in India. So we have in -- plus, as you know, we have a new innovation center in Shanghai. So from a front end of the company, sales, marketing, tech service, we are pretty much ready to sell more. We are at 100% capacity, and by 2014, we'll bring that to the market.

Okay. So the extra investments that you talked about that's impacting the margins of the BioPolymer's business, that largely had to do with labs that you opened more so than the CapEx for the MCC expansion, right?

Correct. That's correct.

Your last question will come from the line of Peter Butler of Glen Hill Investment.

I'm wondering if -- could Mark Douglas give us an update on his or your cost reduction programs?

Hi, Peter, it's Mark here. Yes, sure. If you remember back to the Investor Day and consequent calls, we said we would have run rate savings by the end of 2011 of $25 million, an additional $25 million on top of that by the end of 2012 going towards an $18 million run rate of savings by 2015. I can tell you that we beat our $25 million at the end of 2011 by a couple of million dollars, and we are on track to deliver the next $25 million by the end of this year. So things are in -- on track, where we expect it to be. We've built out the organization as I said we would, and we're very much focused on adding value to the company by a very professional procurement organization.

Good, sounds good. Could I ask, please, Pierre, about the -- you've mentioned several times the extra spend on growth initiatives, some in Ag, some in BioPolymer's. I'm wondering is this just normal growth initiatives or is this extra expenditures because maybe your earnings and cash flow are coming along better than you thought and you could spend more?

Yes, Peter. I mean, that's an important question. We believe today -- we truly believe today that we have the capability to deliver significant top line growth and double-digit EPS growth every quarter, but at the same time, take advantage of all of the opportunities we have for future growth. And we believed, after looking into our portfolio of technology pipeline, that we were limited, not by the ideas, not by the portfolio of what we could bring to the market, just by the resource and money. And seeing the growth potential of the company, the earnings potential of the company, we have decided that we can deliver beyond expectations, but still invest more in the future of the company and in the past. So what we called growth initiatives are mostly strengthening our research globally by more resource in North America, but also in other places like Asia or Latin America, more sales, more tech service in order to bring more work on registrations in Ag, so more spending to bring new technology to the market faster. And we've been thinking about should we do that for a couple of years when I joined, but I believe, for a little while, we're going to want to take opportunities or what we have in front of us because we do have lots of positive things which are happening in the company, which will allow us growth for many years.

Okay. And slightly different, you mentioned 3 or 4 or 5 different, nonrecurring, temporary negatives that have impacted your short-term earnings. I know you're not going to want to go through each and -- each one of them and give us a number, but could you sort of aggregate and tell us how much this cost you in the second quarter and what might show up on the bottom line a year from now in the second quarter due to the amelioration of some of these negatives that you had itemized?

Yes. If you look in the big scheme of things, there is only one negative today. It's the performance of the lithium business. We -- I mean, frankly, if you look at all of the businesses, they're all performing very, very strongly currently, and they are going to perform very strongly for the next 3 quarters for the year and beyond. So the major orientation we have in the earning growth despite the -- and despite that, we delivered a 30% year-on-year EPS growth in our lithium business. It is multimillion dollars, I mean, more than single digits, which we're going to see to the bottom line in between the first quarter and the fourth quarter this year in term of amelioration of the financial performance of that business. So what we really have to focus on today is keep on operating all of our businesses as strongly as they have been performing and turn around the Lithium business. And we know exactly where the issues are, so you will start to see some improvement in Q2, some in Q3, and you will see the full earning potential of that business in Q4. The rest -- yes, there is some issues right and left, but there is some positive. They pretty much offset each other, and they do not impact majorly the performance of the company.

Well, I was thinking whatever this number is, it's a pretty sizable number in the first half and sort of builds in a very nice earnings gain year-to-year, that should show up next year in the first half.

Yes. I mean, if you look at -- I think we delivered it -- I mean, I'm pretty, pretty pleased with the quarter we delivered. It's a great thing to be able to talk about a company delivering quarter-on-quarter performance, 30% up in term of earnings. Looking at a year, we're going to have a -- I think, a midpoint of our guidance is around 16% EPS growth, which is a strong performance. And when you know that we're delivering that, with 4 business out of 5 performing, and we have 1 with strong earnings growth potential. And when you -- you have to believe that those 5 businesses will be operating at full potential in the fourth quarter, that tells you the magnitude of improvement we can see demonstrating to a 30% now.

I will now turn the call back to Mr. Brondeau for his closing remarks.

Thank you very much to all for your time, your attentions and your questions. I hope that during today's call, we have demonstrated again our ability to deliver strong performance quarter-after-quarter, while at the same time continue to make well-placed organic and external investments to ensure our future profitable growth. We delivered 2 superb years in 2010 and 2011 and are off a strong start in 2012. We are confident that we will continue to realize the earnings power investors should expect from the FMC portfolio. 1.5 years ago, we shared with you a plan with our overriding objective to drive top quartile total shareholder return. It has an aggressive organic growth component, which would be augmented by a focused external growth component. As we say, we were to realize this aggressive growth, we have made targeted increases in our below-the-line costs. We have increased research and development spending, especially in Agricultural Products and BioPolymer. We had increased selling and technical service expenses, and we had invested in critical infrastructure to deliver this growth where it is needed. The vast majority of this spend is out in the business and regions where it should be, close to our customers. We are fortunate that today, we have a rich organic growth pipeline that will leverage our strong new product and technology innovation expertise. Equally, we have a rich external pipeline that offers us the opportunity to make focused equity and acquisitions. Our success here is evident. In 2012, we will derive $90 million in sales and $15 million in EBIT and EPS of $0.07 from the 8 transactions we completed in 2011. Including the related organic growth investments to fund the growth of each of these transactions, we are on track to meet our goal for external growth to contribute $800 million or more in 2015 revenues. So in summary, I can say that now, more than ever, we are confident that 2012 will be another record year for FMC, that we are solidly on track to achieve our Vision 2015 objective, and equally importantly, that we are building a company that will deliver premium growth and value well beyond 2015. I look forward to providing you an update on the Vision 2015 progress during next quarter's call, and I look forward to presenting an in-depth review of our Vision 2015 strategy at an Investor Day to be held on Tuesday, December 11, 2012, in New York City. Details will be forthcoming. Thanks, again, for your time and attention. This completes our call.

Thank you. This concludes the FMC Corporation's First Quarter 2012 Earnings Release Conference Call.